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Abstract: Blood–brain barrier (BBB) dysfunction is a key hallmark in the pathology of many neu-
roinflammatory disorders. Extracellular vesicles (EVs) are lipid membrane-enclosed carriers of mo-
lecular cargo that are involved in cell-to-cell communication. Circulating endothelial EVs are in-
creased in the plasma of patients with neurological disorders, and immune cell-derived EVs are 
known to modulate cerebrovascular functions. However, little is known about whether brain endo-
thelial cell (BEC)-derived EVs themselves contribute to BBB dysfunction. Human cerebral micro-
vascular cells (hCMEC/D3) were treated with TNFα and IFNy, and the EVs were isolated and char-
acterised. The effect of EVs on BBB transendothelial resistance (TEER) and leukocyte adhesion in 
hCMEC/D3 cells was measured by electric substrate cell-substrate impedance sensing and the flow-
based T-cell adhesion assay. EV-induced molecular changes in recipient hCMEC/D3 cells were an-
alysed by RT-qPCR and Western blotting. A stimulation of naïve hCMEC/D3 cells with small EVs 
(sEVs) reduced the TEER and increased the shear-resistant T-cell adhesion. The levels of microRNA-
155, VCAM1 and ICAM1 were increased in sEV-treated hCMEC/D3 cells. Blocking the expression 
of VCAM1, but not of ICAM1, prevented sEV-mediated T-cell adhesion to brain endothelia. These 
results suggest that sEVs derived from inflamed BECs promote cerebrovascular dysfunction. These 
findings may provide new insights into the mechanisms involving neuroinflammatory disorders. 




BECs are the main cellular component of the BBB, a specialised feature of the vascu-
lature of the central nervous system (CNS) [1]. BEC dysfunction is common in neuroin-
flammatory pathologies like multiple sclerosis (MS) [2]. Inflammatory modulators such 
as proinflammatory cytokines are upregulated in the plasma of individuals with MS and 
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other conditions such as sepsis [3,4]. Cytokines play an additional central role in the pro-
gression of inflammation by acting on the BBB. For instance, tumour necrosis factor alpha 
(TNFα) and interferon gamma (IFNy) modulate the vascular function by increasing the 
paracellular permeability [5] and leukocyte adhesion to BECs and migrationf across BECs 
[6,7]. BECs express junctional complexes that contain tight junctional (TJs) and adherens 
junctional (AJs) proteins that are linked to the cytoskeleton via scaffolding proteins such 
as zona occludens-1 (ZO-1) and which confer the barrier properties of the BBB [8]. The 
expression and location of these complexes are altered in the vasculature in MS lesions [9] 
and in cytokine-treated BECs [10].  
In addition to cytokines, vascular functions are also modulated by EVs [11]. EVs are 
lipid membrane-enclosed carriers of many different molecules, including proteins and 
both coding and non-coding RNAs (e.g., microRNAs (miRNAs)) that can influence the 
protein expression and the function of recipient cells [12]. EVs represent a heterogeneous 
population, but they are typically classified into apoptotic bodies, microvesicles and exo-
somes [13]. Apoptotic bodies are larger vesicles (500–5000 nm) that are produced as a con-
sequence of cells undergoing apoptosis [12]. Microvesicles (100–1000 nm) are generated 
by the direct outward budding of the plasma membrane, whereas exosomes (30–200 nm) 
are produced intracellularly after the fusion of the multivesicular body with the plasma 
membrane and are released into the extracellular space [14]. Recent reports have high-
lighted the heterogeneous nature of EVs and the existence of additional EV subpopula-
tions [15,16]. Due to the lack of optimal methods to isolate and identify specific EV popu-
lations, the current International Society of Extracellular Vesicles (ISEV) guidelines [12] 
recommends the classification of EVs as either small EVs (sEVs) (<200 nm) or large EVs 
(L-EVs) (200 nm–1000 nm), unless the specific EV origin is known.  
The precise role of EVs in the pathogenesis of MS is still unclear, but the number of 
circulating EVs has been shown to be increased in the plasma of patients with neuroin-
flammatory conditions [17]. Marcos-Ramiro and colleagues observed an increase in the 
number of endothelial-derived EVs in the plasma of MS patients compared to healthy 
controls [18]. They also observed that plasma-derived EVs reduced the expression of TJ 
protein zona-occludens (ZO-1) at the junctional area and decreased the electrical re-
sistance of BECs. Yamamoto et al. suggested that EVs containing inflammation-induced 
miRNAs that were isolated from mouse BECs modulated the transcriptome of recipient 
pericytes [19]. In another study, EVs derived from human brain endothelial cells after 
treatment with the proinflammatory cytokine TNFα were found to carry higher levels of 
proinflammatory proteins (e.g., intercellular adhesion molecules 1 (ICAM1) and vascular 
cell adhesion molecule 1 (VCAM1)) compared to EVs isolated from naïve cells [20]. 
The role of BEC-derived EVs in cerebrovascular function generally, and in the context 
of inflammation specifically, is still poorly understood. Therefore, the aim of this study 
was to investigate the role of EVs derived from cytokine-challenged BECs (cytokine-EVs) 
in cerebrovascular functions. We found that the cytokine challenge of hCMEC/D3 cells 
induced an increased release of sEVs that contained proinflammatory modulators. The 
incubation of naïve BECs with these sEVs decreased the tightness of the endothelial mon-
olayer and increased the T-cell adhesion to the endothelium. These findings suggest that 
the damage to the BBB during a neuroinflammatory insult may result in part from a feed-
forward mechanism in which the uptake of EVs secreted from inflamed BECs by naïve 
cells induces a proinflammatory environment in the recipient BECs. These results may 
have implications for the pathophysiology of neuroinflammatory conditions in the brain 
vasculature.  
2. Materials and Methods 
2.1. Cell Culture 
The hCMEC/D3 cell line was cultured in endothelial cell basal medium-2 (EBM-2) 
supplemented with 0.025% (v/v) recombinant human epithelial growth factor (rhEGF), 
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0.025% (v/v) vascular endothelial growth factor (VEGF), 0.025% (v/v) insulin growth factor 
(IGF), 0.1% (v/v) recombinant human fibroblast growth factor (rhFGF), 0.1% (v/v) gen-
tamycin, 0.1% (v/v) ascorbic acid, 0.04% (v/v) hydrocortisone and 2.5% (v/v) foetal bovine 
serum (FBS) (Lonza, Wilford, Nottinghamshire, UK), hereafter referred to as the endothe-
lial complete medium. hCMEC/D3 cells were used from passages 25–35 and grown in calf 
skin collagen-coated tissue culture flasks until confluence unless otherwise indicated. The 
T-cell line Jurkat from acute T cells was a kind gift from Dr V Male (Cambridge University, 
UK). Jurkat cells were grown in suspension in RPMI 1640 with GLUTAMAX I 
(Gibco® Invitrogen, Paisley, Renfrewshire, UK) culture medium containing 10% (v/v) FBS 
and 100-μg/mL streptomycin + 100-units/mL penicillin (P/S). All cell lines were main-
tained in a 95% humidified air and 5% CO2 incubator at 37 °C. The cells were routinely 
screened for the presence of mycoplasma using the MycoAlert Mycoplasma kit (Lonza, 
Wilford, Nottinghamshire, UK). 
2.2. Isolation of Brain Endothelial Cell-Derived Extracellular Vesicles 
2.2.1. Conditioned Cell Media Preparation 
The isolation of BEC-derived EVs was carried out using hCMEC/D3 cells cultured in 
collagen-coated 175-cm2 tissue culture flasks for 48 h. Then, the cells underwent three 
Hanks Balanced Salt Solution (HBSS) washes before the cell culture media was replaced 
by 15 mL of endothelial complete medium supplemented with 2.5% EV-depleted FBS 
(hereafter referred to as sEV medium) (Gibco® Invitrogen, Paisley, UK). A combination of 
10 ng/mL of both TNFa and IFNy diluted in cell sEV medium was used to treat 
hCMEC/D3 cells. Cells incubated with only cell sEV medium were used as the control. 
The cell-conditioned medium (CCM) was collected 24 h after the media exchange when 
the cells reached 95–100% confluency (approximately 15 × 106 cells per 175-cm2 tissue cul-
ture flask). To remove living/dead cells, CCM was centrifuged at 3″× g for 10 min (min). 
Then, the cell debris was depleted by centrifugating CCM at 2000× g for 20 min.  
2.2.2. Isolation of Large Extracellular Vesicles 
To isolate L-EVs, CCM was centrifuged at 10,000× g for 30 min, followed by a wash 
using 30 mL of 1× phosphate-buffered saline (PBS). Resuspended L-EVs were filtered by 
a 0.8-µm sterile filtered unit and centrifuged at 10,000× g for 30 min. The L-EVs were 
stored at -80 °C for up to two months to minimise the degradation of the RNA and vesicle 
number [21]. 
2.2.3. Isolation of Small Extracellular Vesicles 
Isolation of the sEVs was perform on the supernatant from the first L-EV centrifuga-
tion. Due to the small size of sEVs, ultracentrifugation at 120,000× g for 120 min was per-
formed on CCM and followed by resuspending the pellet in 30 mL of PBS and repeating 
the 120,000× g spin for 120 min. Pelleted sEVs were resuspended in the appropriate buffer 
(PBS, endothelial sEV medium lacking IGF, EGF, VEGF and FBS or RNA/protein lysis 
buffer). The aliquots were stored at −80 °C for up to two months. A Rhe Sorvall Discovery 
(Brea, CA, USA) Superspin 630 Sorvall rotor (k factor 226.3) was used to perform all the 
ultracentrifugation steps, which were carried out at 4 °C.  
Endothelial-Derived Extracellular Vesicles Characterisation 
A NS500 nanoparticle analyser (NanoSight, Malvern, Worcestershire, UK) was used 
for the nanoparticle tracking analysis (NTA). The particles appeared as sharp individual 
dots after adjusting the camera focus. Three 30-s videos were recorded for each sample, 
with a delay of 5 s between each recording.  
For transmission electron microscopy (TEM) of the EV samples, 10 µL of either L-
EVs or sEVs was mixed 1:1 with 4% (w/v) paraformaldehyde (PFA). A 5-µL drop of this 
mix was incubated in a Formvar carbon-coated grid for 20 min at room temperature (RT). 
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The grids were washed in PBS and incubated with 2.5% (v/v) glutaraldehyde for 5 min at 
RT. Glutaraldehyde was washed in distilled water for 2 min seven times. The grids were 
then counter-stained with 3.5% (w/v) of uranyl acetate for 20 s. The grids were air-dried 
and were observed under TEM (JEM1400) at 80 kV. 
TNFα and IFNγ ELISA 
An enzyme-linked immunosorbent assay (ELISA) from the DuoSet®  kit (R&D Sys-
tems, Abingdon, Oxfordshire, UK) was used to measure the residual levels of TNFα and 
IFNγ in sEVs following the manufacturer’s instructions. Briefly, 96-well plates were 
coated with either anti-TNFα or anti-IFNγ capture antibodies, washed and blocked in 
0.1% (w/v) bovine serum albumin (BSA). The cytokine standards and sEVs (108 sEVs/µL) 
were loaded onto the plates, incubated for 2 h at RT, then washed and the secondary an-
tibody was added for one extra hour at RT. Then, the wash step was repeated, followed 
by the addition of the substrate solution. The plates were incubated for 20 min before the 
reaction was stopped. The signal was measured using a FLUOstar Optima fluorescence 
plate reader (BMG LABTECH, Aylesbury, UK) at 450 nm, and the background was sub-
tracted by measuring the wavelength at 570 nm. 
Uptake of Endothelial-Derived Small EVs 
For the uptake experiments, the sEVs were prepared following Section 2.2. However, 
after the first 120,000× g centrifugations, the sEVs were labelled with 10% (v/v) Vybrant-
DiO (Life technology, Paisley, UK) diluted in 5 mL of PBS for 30 min at 37 °C. Vybrant-
DiO was added in the same ratio to PBS, and the sample was treated in the same manner 
and used as a control for any free Vybrant-DiO dye left in the solution.  
BECs were grown in 12-well plates to sub-confluence (95%) and incubated with DiO-
labelled sEVs at the concentrations (from 0.1 to 108 sEVs/µL) and times (from 6 to 48 h) 
specified in each figure. Then, the washed and tripsised cells were analysed on the FACs 
Calibur (Becton-Dickinson, Berkshire, Reading, UK) (FL1 detector set at 530 V). The me-
dian fluorescence of 10,000 cell events were reported. Collagen- and fibronectin- coated 
Nunc®  Labteck chamber slides were used to grow hCMEC/D3, as described elsewhere 
[22]. Then, 0.5 × 108 cells/µL DiO-labelled sEVs were incubated with hCMEC/D3 cells for 
6, 24 and 48 h. Then, the cells were fixed in 4% (w/v) PFA for 10 min at RT. The slides were 
mounted with mounting media containing DAPI dye (Vector Laboratories, Burlingame, 
CA, USA) for nuclear staining. The acquisition and analysis of the images were performed 
using confocal laser scanning microscopy (Leica TCS SP5, Leica Microsystems, Milton 
Keynes, UK). The images were shown as the maximum projection of a z-stack of images. 
Electric Cell-Substrate Impedance Sensing (ECIS) 
ECIS Z-Theta (Applied BioPhysics, Troy, NY, USA) was used to measure the TEER 
of the hCMEC/D3 cell monolayer in real time, as described previously (Keese et al. 2004). 
Twenty-thousand cells were seeded onto each well of a 96W10E+ array previously coated 
with calf skin collagen type I and grown until confluence. The cells were treated with sEVs 
at the doses (from 0.1 to 108 sEVs/µL) described at the figure legends. A small amount (1 
ng/mL) of TNFα and IFNγ was used as the positive control to induce the loss of endothe-
lial resistance. Impedance data were collected at multiple frequencies and mathematically 
modelled to calculate the resistivity of cell–cell contacts Rb (Ω × cm2) at each time point 
measured [23]. Rb data are shown as a percentage of the control at each time point.  
Paracellular Permeability Assay 
The effect of cytokine-sEVs on hCMEC/D3 cells was studied following a paracellular 
permeability assay previously described elsewhere [24,25]. Briefly, confluent hCMEC/D3 
cells were incubated with 0.1 cytokine-sEVs/µL for 6, 24 and 48 h. Then, the apical media 
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was replaced by 2 mg/mL of 70-KDa FITC-dextran in phenol red-free DMEM. The fluo-
rescent signal in the basolateral chamber was read every 5 min during a 30-min window 
using a BMG plate reader and the derived permeability coefficient Pe [24]. 
Leukocyte Adhesion to Endothelium under Flow Conditions 
T-cell adhesion was measured using a flow-based adhesion assay adapted from pre-
viously published data [26,27]. Briefly, hCMEC/D3 cells were grown in Ibidi®  μ-Slide 
VI0.4 (Ibidi®  GmbH, Martinstreid, Germany) until they reached confluence, then incu-
bated with sEVs at the doses (from 0.1 to 108 sEVs/µL) and times (from 6 to 48 h) described 
in their specific figure legends in static conditions and washed before the flow adhesion 
assay. The positive control consisted of 1-ng/mL TNFα and IFNγ incubation for 24 h [28]. 
To address the functions of VCAM1 and ICAM1 in this study, 30 µg/mL of neutralising 
antibodies against ICAM1, VCAM1 or the control mouse IgG (R&D Systems, Abingdon, 
Oxfordshire, UK) were added to washed hCMEC/D3 cells and incubated for 1 h at 37 °C 
in EBM-2 basal media. Some (2 × 106 cells/mL) Jurkat T cells were labelled with 5-µM 5–
chloromethylfluoresceindiacetate (CMFDA, Life Technologies, Eugene, USA). The cells 
flowed through the channel containing endothelial monolayers at 0.5 dyn/cm2 for 5 min. 
Subsequently, the flow was increased to 1.5 dyn/cm2 for 1 min to remove non-adhered 
leukocytes. Interactions between the leukocyte and endothelial cells were recorded for 6 
min; following which, the leukocyte adhesion was quantified. Five to ten different fields 
of vision (FOVs) along the centre of the channel were imaged using an inverted fluores-
cence microscope (Olympus IX70, Tokyo, Japan) with a ×10 objective. The firmly adhered 
leukocytes were counted manually.  
RT-qPCR  
The RNA was isolated from either cultured cells or the sEV pellet using a miRCURY 
Exiqon kit (Qiagen, Manchester, Greater Manchester, UK) following manufacturer’s in-
structions. Briefly, the cells or sEV pellet were incubated with the lysis buffer, homoge-
nised by vortexing and precipitated with pure ethanol. The samples were cleaned and 
concentrated using miRCURY columns, washed and eluted in 50 µL of elution buffer. The 
RNA concentration and quality was measured using Nanodrop ONE (Life technology, 
Paisley, Renfrewshire, UK). 
To investigate the effects of the cytokines and sEVs on the transcriptomes of BECs, 
hCMEC/D3 cells were grown to confluence and treated with 108 sEVs/µL or 10 ng/mL of 
cytokines (TNFα and IFNy) for 24 h. The RNA was isolated as described above. Reverse 
transcription for microRNAs was performed using a Taqman microRNA transcription kit 
with specific Taqman primers for miRNA-155-5p, 126-5p, 126-3p, 24, 146a and 146b follow-
ing the manufacturer’s instructions. Small nuclear RNA U6 (U6) was used as the control 
in BECs, whereas let-7g was used as the control of the microRNAs levels in sEVs [29]. For 
the mRNA analysis, total cDNA was generated using a TaqMan High-Capacity cDNA 
Reverse Transcription kit (Applied Biosystem, Life Technologies, Warrington, Lancashire, 
UK) using random primers. Quantitect SyberGreen master mix (Qiagen, Manchester, 
Greater Manchester, UK) was used to study the relative levels of the mRNAs with 10 ng 
of cDNA. Primers for ICAM1, VCAM1 and Carcinoembryonic antigen-related cell adhe-
sion molecule 1 (CEACAM1) were tested, and β-actin was used as a housekeeping gene 
(Merk Millipore, Watford, Hertfordshire, UK). 
The relative amounts of microRNA and mRNA were calculated using the 2−ΔΔCt 
(delta-delta Ct) method [30] and normalised with the appropriate available internal con-
trol. The relative levels of microRNA/mRNA in treated hCMEC/D3 cells or cytokine-sEVs 
were expressed as fold changes over levels in unstimulated hCMEC/D3 cells or quiescent 
sEVs, respectively. 
  




Isolated cytokine-sEVs or hCMEC/D3 cells were resuspended in 1× RIPA Buffer (20-
mM Tris-HCl (pH 8.0), 150-mM NaCl, 1-mM EDTA, 0.1% SDS, 1% Igepal, 50-mM NaF 
and 1-mM NaVO3) supplemented with protease inhibitor cocktail (Merk Millipore, Wat-
ford, Hertfordshire, UK). The samples were sonicated (Fisherbrand™ Model 120 Sonic 
Dismembrator) at 20% amplitude for 10 s on ice. The protein concentration was measured 
using a DC™ Protein Assay kit (Bio-Rad Laboratories Ltd., Watford, Hertfordshire UK). 
The samples were mixed with 2× Tris glycine sample buffer (Life Technologies, Paisley, 
Renfrewshire, UK), and the proteins were denatured by heating the sample at 75 °C for 5 
min. Five micrograms of cytokine-sEV sample or 20 µg of cell lysate were loaded in 4–
20% Tris-Glycine gels (Life technology, UK) and run at 120 V for 2 h. The proteins were 
transferred to a nitrocellulose membrane, and the membrane was blocked with 8% (w/v) 
skimmed milk diluted in Tris buffer saline containing 0.2% w/v Tween-20 (TBS-T). The 
membranes were incubated overnight at 4 °C with primary antibodies diluted in 8% (w/v) 
skimmed milk diluted in TBS-T. For sEV characterisation, the membranes were incubated 
with rabbit anti-mouse primary antibodies against CD9, CD63 or HSP70 (System Biosci-
ence Palo Alto, CA, USA) at 1:1000. Membranes containing hCMEC/D3 lysates were incu-
bated with mouse anti-human VCAM1 (1:300) and ICAM1 (1:300) (R&D Systems, Abing-
don, Oxfordshire, UK), rabbit anti-human occludin (1:150) and claudin-5 (1:150) (Life tech-
nology, UK). Then, three 10-min washes with TSB-T were applied to the membranes, fol-
lowed by an incubation with the appropriate secondary antibody, goat anti-rabbit or anti-
mouse HRP (System Bioscience Palo Alto, CA, USA) at 1:5000 in 8% (w/v) of skimmed 
milk diluted in TBS-T for 60 min at RT. Subsequently, the membranes were washed 6 
times with TBS-T for 10 min, followed by incubation with an enhanced chemilumines-
cence reagent (ECL) (GE Healthcare, Little Chalfont, Buckinghamshire, UK). The mem-
branes were visualised using G:Box (Syngene, Cambridge, Cambridgeshire, UK) 
Statistical Analysis 
All data were presented as the mean ± SD (standard deviation). The number of inde-
pendent experiments (n) with replicates was specified in each legend. The normality was 
assessed with the Shapiro–Wilk test, p = 0.05. The means were compared using unpaired 
or paired two-tailed t-tests for single comparisons and one-way or two-way ANOVA for 
multiple comparisons. The ANOVA analysis was followed by Dunnett’s or Tukey’s mul-
tiple comparisons tests. The specific analysis was specified in each figure legend. The nor-
mality of the data was assessed by the Shapiro–Wilk test. All tests were performed using 
the statistical software GraphPad Prism 7 (GraphPad Software, San Diego, CA, USA). p < 
0.05 was considered to be statistically significant.  
3. Results 
3.1. hCMEC/D3 Cells Secrete More Small EVs Than Large EVs after Treatment with TNFα and 
IFNγ 
To determine the effect of an inflammatory challenge on EV secretion, the number, 
size and morphology of EVs isolated from naïve BECs and BECs treated with proinflam-
matory cytokines (Figure 1a) was characterised using NTA, TEM and Western blotting. 
The NTA analysis revealed that the stimulation with proinflammatory cytokines in-
creased the number of both cytokine-sEVs and a trend for number of cytokine-L-EVs (Fig-
ure 1b). The size distribution showed heterogeneous populations of sEVs and L-EVs (Fig-
ure 1c,e). The cytokine treatment had no effect on the mode of the diameter of both sEVs 
and L-EVs (Figure 1c). However, the size range of cytokine-L-EVs measured by D90 was 
greater than the rest of the isolated EV groups (Figure 1d). D10, D50 and D90 values indi-
cate the percentage of particles (10, 50 and 90%, respectively) less than or equal to the 
corresponding particle size [31] (Figure 1e). 
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TEM revealed lipid-based structures with a spherical shape for larger vesicles (>200 
nm) and a mix of spherical and cup-shaped morphology for smaller vesicles (<200 nm) 
(Figure 1f). As previously reported (Dozio and Sanchez 2017), cytokine-sEVs expressed 
markers of EVs, including CD9, CD63 and HSP70, which were also expressed in the cell 
lysate (Figure 1g).  
To evaluate how efficiently the method of EV isolation separated soluble cytokines 
from cytokine-sEVs, conditioned cell media (CCM) and sEVs were assessed for concen-
trations of TNFα and IFNγ. The concentration of residual TNFα and IFNy in the CCM 
following a 24-h cytokine incubation with BECs was 1.95 ± 0.52 and 2.37 ± 0.94 ng/mL, 
respectively. In isolated EVs, concentrations of TNFα and IFNy were 0.012 ± 0.014 ng/mL 
and 0.015 ± 0.008 ng/mL, respectively (Figure 1h), suggesting that less than 1% of residual 
TNFα and IFNγ was contained within the EV mixture.  
 
Figure 1. Characterisation of extracellular vesicles in inflammation. (a) Graphic diagram of the isolation of extracellular 
vesicles (EVs) both small (sEVs) and large (L-EVs) from untreated hCMEC/D3 cells (quiescent sEVs or L-EVs) and those 
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incubated with 10-ng/mL TNFα and IFNy (cytokine-sEVs or -L-EVs) for 24h using a combination of ultracentrifugation 
(dUC) and filtration steps. (b) Nanoparticle tracking analysis (NTA) measurements of isolated EVs revealed significantly 
increased numbers of cytokine-sEVs after the cytokine treatment compared to the controls. (c) Size distribution measured 
by NTA showed that most isolated EVs were smaller than 200 nm in all EV subsets (left image shows sEVs, whereas the 
right image shows L-EVs). (d) Representative images of cytokine-sEVs and L-EVs from the Nanoparticle Tracking Analy-
sis (e) The table summarises the mean; mode and D10, D50 and D90 diameter sizes of sEVs and L-EVS. (f). Transmission 
electron microscopy (TEM) images of cytokine-sEVs and cytokine-L-EVs. Arrows point to sEVs in both images. (g) Im-
munoblots for CD9, CD63 and HSP70 in cytokine-sEVs (sEV) and cell lysate (CL) controls. (h) Concentrations of TNFα 
and IFNy in the cytokine-sEV fractions and cell-conditioned medium (CCM). Data are shown as the mean ± SEM, n = 2 
(d), n = 3 (f) and n = 4 (b,c). The means were compared with one-way ANOVA, followed by Tukey ś post-hoc test. * p < 
0.05, ## or ** p < 0.01, *** p < 0.001 and **** p < 0.0001. 
3.2. Uptake of Small EVs by Brain Endothelium Is Time- and Dose-Dependent 
To determine the kinetics of the uptake of cytokine-sEVs by BECs, cytokine-sEVs 
were labelled with the lipophilic dye DiO, and their uptake by hCMEC/D3 cells was ana-
lysed using confocal microscopy and flow cytometry. Confocal microscopy showed a pre-
dominately perinuclear localisation of DiO staining with some staining dispersed in the 
cytoplasm (Figure 2a). The EV uptake was qualitatively similar at the 24-h and 48-h time 
points, suggesting that a level of saturation was achieved by 24 h. Based on these obser-
vations, we chose the 24-h end point for the dose response experiments using flow cytom-
etry. A flow cytometry analysis of the mean fluorescence of DiO-labelled cytokine-sEVs 
revealed that the uptake of cytokine-sEVs by hCMEC/D3 cells was also dose-dependent 
(Figure 2b).  
 
Figure 2. Characterisation of the uptake of cytokine-sEVs by naïve brain endothelium. (a) Confocal images of the uptake 
of 0.5 × 108 DiO-labelled cytokine-sEVs/µL by human microvascular brain endothelial cells (hCMEC/D3 cells) at different 
time points (0, 6, 24 and 48 h). (b) Flow cytometry measurements of DIO-labelled cytokine-sEVs incubated with 
hCMEC/D3. The graph shows a quantification of the median fluorescent intensity (MFI) of the uptake of cytokine-sEVs 
(0.1, 0.5 and 1×108 sEVs/µL) by naïve hCMEC/D3 cells. Data is shown as the mean ± SEM (n = 3). The means were compared 
with one-way ANOVA followed by Tukey ś multiple comparison test. * p < 0.05 and *** p < 0.001. 
3.3. Cytokine-Derived Small EVS Modulate the Transendothelial Resistance 
The loss of paracellular barrier function is an established characteristic of brain en-
dothelial cell dysfunction, which can be studied by measuring the electrical impedance of 
the endothelial monolayer [32]. Thus, we evaluated the effect of cytokine-sEVs on the im-
pedance of BECs. A dose-dependent decrease of the TEER values was observed after the 
incubation of hCMEC/D3 cells with cytokine-sEVs (0.1, 0.5 and 1 × 108 sEVs/µL) (Figure 
3a). We observed a peak in decreased TEER at 83 ± 6% in comparison to the control cells 
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with 1 × 108 cytokine-sEVs/µL. However, longer incubation times did not cause a further 
decrease in TEER (Figure 3a). Next, hCMEC/D3 cells were treated with either quiescent 
BECs or cytokine-treated BECs (0.5 × 108 sEVs/µL) to further characterise the specific effect 
of cytokine-sEVs on TEER. We observed that, after 10 h of incubation with sEVs, a de-
creased endothelial resistance was only observed in sEVs derived from cytokine-activated 
hCMEC/D3 cells (Figure 3b). No significant effect was observed with quiescent sEVs. To 
further confirm the role of cytokine-sEVs modulating the BBB permeability, the para-cel-
lular permeability of 4-KDa FITC-Dextran was evaluated (Figure 3c). Incubation with 0.1 
× 108 cytokine-sEVs/uL showed a small but significant increase in para-cellular permea-
bility after 6 h of treatment. This effect was transient, since a longer incubation only 
showed a small trend for increased para-cellular permeability. 
 
Figure 3. Cytokine-sEVs decrease the transendothelial resistance of hCMEC/D3 cells. (a) TEER values following 
hCMEC/D3 cells with varying concentrations of cytokine-derived small EVs (cytokine-sEVs) (0.1, 0.5 and 1 × 108 sEVs/µL). 
Data are shown as the percentage fold change of treated relative to untreated cells at each time point. (b) Comparison of 
the effects of 0.5 × 108 sEVs/µL cytokine-sEVs and quiescent sEVs on the TEER values. (c) Para-cellular permeability ex-
periment of 70-KDa FITC-Dextran after a 0.1 × 108 cytokine-sEVs/ul stimulation for 6, 24 and 48 h. Data is shown as the 
mean ± SEM. The means are compared by two-way ANOVA followed by Tukey ś post-hoc for multiple comparisons, n = 
3 (b) and 4 (a). * p < 0.05, ** p < 0.01, *** and p < 0.001 compared to untreated cells. 
3.4. Adhesion of T Cells to Brain Endothelium Is Modulated by Cytokine-sEVs 
T-cell adhesion to BECs is a main feature of endothelial dysfunction in neuroinflam-
mation [33]. Therefore, we decided to investigate the effect of cytokine-sEVs on T-cell ad-
hesion to brain endothelia. For this, we used a flow-based assay in order to expose the 
cells to shear stress, which has been demonstrated to more closely mimic in vivo condi-
tions [34]. The interaction of Jurkat T cells with hCMEC/D3 cells was studied using time-
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lapse microscopy (Figure 4a). A concentration-dependent increase in adhesion was ob-
served, with a peak at 1 × 108 cytokine-sEV/µL of 96 ± 23 firmly adhered Jurkat T cells per 
FOV (Figure 4b). In accordance with the results from the TEER experiments, a rapid in-
crease of T-cell adhesion to BECs was observed after 6 h of incubation and was stable at 
later time points (Figure 4c). The T-cell adhesion after incubation with cytokine-sEVs was 
approximately half that of the number of cells that adhered after the incubation of BECs 
with 1 ng/mL of TNFα and IFNy (Figure 4b). Quiescent sEVs had no effect on the T-cell 
adhesion to naïve brain endothelium (Figure 4d). 
 
Figure 4. Cytokine-sEVs increase Jurkat T-cell adhesion to the brain endothelium. (a) Representative brightfield (top) and 
fluorescent (FITC, bottom) images of Jurkat T-cell adhesion (round-shaped cells) to hCMEC/D3 cells (spindle-shaped cells) 
under flow conditions in their absence (control, left panels), with the addition of cytokine-derived small EVs (cytokine-
sEVs) (middle panels) or cytokines (1-ng/mL TNFα + IFNy, right panels). (b) Quantification of the number of firmly ad-
hered T cells per field of view (FAJCN) (FOV 640 × 480 μm) following incubation with increasing doses of cytokine-sEVs 
(0.1, 0.5 and 1 × 108 cytokine-sEVs/µL) for 24 h. (c) Time–course analysis (6, 24 and 48 h) of the effect of 1 × 108 cytokine-
sEVs on FAJCN on naïve endothelium. (d) Comparison of cytokine-sEVs and quiescent sEVs (0.5 × 108 sEVs/µL for 24 h) 
on FACJN in naïve hCMEC/D3 cells. Data is shown as the mean ± SEM, and n = 4 (b,c) and 3 (d). The means are compared 
by one-way ANOVA followed by Dunnett ś post-hoc for multiple comparisons, * p < 0.05 and ** p < 0.01 and *** p < 0.001 
to the untreated condition. 
3.5. Levels of Proinflammatory miRNA-155-5p and Adhesion Molecule mRNAs Are Increased in 
the Cargo of Cytokine-sEVs 
Since EVs are known to carry genetic material that may influence BEC functions, we 
next decided to investigate the differences in the miRNA contents of cytokine-sEVs com-
pared to quiescent sEVs. We first selected a series of miRNAs that are known to be upreg-
ulated (miRNA-155-5p, miRNA-146a and miRNA-146b); downregulated (miRNA-126-5p 
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and miRNA-126-3p) or unchanged (miRNA-24) in hCMEC/D3 cells after treatment with 
TNFα and IFNy and whose role in modulating hCMEC/D3 functions is known [35]. All 
miRNAs were detectable in both cytokine- and quiescent sEVs (Figure 5a). The RT-qPCR 
analysis of the vesicle cargo revealed that the miRNA-155-5p expression was increased 
8.20 ± 2.10-fold (p = 0.004) in cytokine-sEVs compared to quiescent EVs (Figure 5a). The 
anti-inflammatory miRNA-126-3p showed a trend towards downregulation in cytokine-
sEVs (0.75 ± 0.56-fold change, p = 0.49), but this was not statistically significant (Figure 5a). 
No difference was observed in the expression of miRNA-146a, -146b, 126-5p and -24 be-
tween quiescent and cytokine-sEVs (Figure 5a). The levels of miRNA-155-5p in cytokine-
sEVs were confirmed to correspond with the endogenous expression of this miRNA in 
BECs after stimulation with 10 ng/mL of TNFα and IFNy for 24 h (6.40 ± 0.98-fold change, 
p = 0.0007) (Figure 5b). We also investigated the relative levels of mRNAs that are directly 
involved in T-cell adhesion and observed that ICAM1 mRNA was significantly increased 
in cytokine-sEVs (6.21 ± 2.29, p = 0.017), whereas VCAM1 mRNA showed a strong trend 
(3.77 ± 1.62, p = 0.054) (Figure 5c). Similar to previous reports [22], the upregulation of 
ICAM1 and VCAM1 mRNAs was also observed in hCMEC/D3 cells upon cytokine treat-
ment (Figure 5d). By contrast, the mRNA levels of carcinoembryonic antigen-related cell 
adhesion molecule 1 (CEACAM1) were not changed in cytokine-sEVs (0.99 ± 0.70, p = 0.79) 
(Figure 5c). 
 
Figure 5. Characterisation of inflammation-related miRNAs and mRNAs in sEV and secreting hCMEC/D3 cells. (a) Quan-
tification of levels of miRNA-155-5p, miRNA-146a, miRNA-146b, miRNA-126-5p, miRNA-126-3p and miRNA-24 in cytokine-
sEVs and quiescent sEVs. (b) Levels of miRNA-155-5p in naïve hCMEC/D3 cells and those treated with 10-ng/mL TNFα 
and IFNy. (c). mRNA levels of vascular cell adhesion molecule (VCAM1), intercellular adhesion molecule (ICAM1) and 
carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in cytokine-sEVs and quiescent sEVs. (d) Levels 
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of VCAM1 and ICAM1 mRNA in naïve hCMEC/D3 cells and those treated with 10-ng/mL TNFα and IFNy. Data are shown 
as the mean ± SEM (n = 3). The means were compared by unpaired two-tailed t-tests, * p < 0.05, ** p < 0.01, *** p < 0.001, **** 
p < 0.0001 compared to quiescent sEV cargos. 
3.6. Cytokine-sEV-Treated hCMEC/D3 Cells Show a Proinflammatory Profile 
Previous studies have suggested that the molecular cargo carried within EVs can be 
transferred to the recipient cells [36]. Therefore, we evaluated the levels of miRNA-155, 
miRNA-126-3p and miRNA-24 in naive BECs treated with cytokine-sEVs or quiescent sEVs 
by qPCR. These miRNAs have been found to be increased, decreased or unchanged in 
inflammation in the brain endothelium, respectively [37]. The levels of miRNA-155-5p 
were significantly upregulated in hCMEC/D3 cells after 24 h of incubation with cytokine-
sEVs (1.46 ± 0.15-fold change, p = 0.0285), whereas the miRNA-155-5p levels were un-
changed after treatment with quiescent sEVs (0.98 ± 0.19, p = 0.9728) (Figure 6a). The ex-
pression of miRNA-126-3p and miRNA-24 was not altered following the sEV treatment 
(Figure 6a).  
In addition, we also investigated the effects of sEV treatment on the mRNA levels of 
genes that are involved in endothelial functions in hCMEC/D3 cells. ICAM1 and VCAM1 
mRNA was upregulated after the treatment with cytokine-sEVs (1.55 ± 0.32, p = 0.0007 and 
1.45 ± 0.13-fold change, p = 0.0053, respectively), whereas they were not changed after 
treatment with quiescent sEVs (Figure 6b). mRNA levels of the TJ protein claudin-5 
(CLDN5) and occludin (OCLN) were not changed following EV incubation. Immunoblot-
ting using primary antibodies against ICAM1, VCAM1 and GAPDH (Figure 6c) con-
firmed a significant upregulation of ICAM1 and VCAM1 in recipient BECs (166 ± 33% and 
534 ± 50% change over untreated cells, p = 0.022 and p = 0.005, respectively) compared to 
untreated hCMEC/D3 cells (Figure 6d). 
Finally, we investigated the role of VCAM1 and ICAM1 proteins in modulating cy-
tokine-sEV-induced T-cell adhesion to the brain endothelium. Blocking ICAM1 did not 
prevent cytokine-sEV-induced T-cell adhesion when compared to IgG-treated hCMEC/D3 
cells (1.93 ± 0.45 and 2.03 ± 0.14-fold change, respectively). By contrast, blocking VCAM1 
significantly reduced T-cell adhesion to BECs (1.31 ± 0.27-fold change and p = 0.040). In 
addition, the simultaneous blockade of VCAM1 and ICAM1 completely prevented the 
effect of cytokine-sEV on T-cell binding to hCMEC/D3 cells (1.04 ± 0.34-fold change and p 
= 0.017) (Figure 6e).  




Figure 6. Cytokine-sEVs induce a proinflammatory profile in recipient hCMEC/D3 cells. (a) Relative levels of miRNA-155-
5p, miRNA-126-3p and miRNA-24 in hCMEC/D3 cells after treatment with cytokine- or quiescent sEVs. (b) Relative levels 
of ICAM1, VCAM1, occludin (OCLDN) and claudin-5 (CLDN5) on hCMEC/D3 cells treated with cytokine- or quiescent 
sEVs for 24 h. (c,d) Immunoblot and quantification of cytokine-sEV-treated or untreated (control) hCMEC/D3 cells for 
ICAM1 and VCAM1. (e) Effect of blocking of ICAM and VCAM alone and in combination with the adhesion of Jurkat T 
cells to untreated or cytokine-sEV-treated hCMEC/D3 cells. Data is shown as the mean ± SEM, n = 3 (a,b,d) and n = 4 (e). 
The means were compared by two-way ANOVA followed by Tukey ś comparison test (a,b) or paired two-tailed t-test (d), 
* p < 0.05, ** p < 0.01 and *** p < 0.001 in comparison to untreated cell levels (a,b,d) or to the IgG control (e). 
4. Discussion 
The findings from the present study indicate that the treatment of BECs with cyto-
kines promotes the release of sEVs with proinflammatory properties that can induce cer-
ebrovascular dysfunction in naïve BEC cells by reducing the endothelial resistance and 
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increasing leukocyte adhesion to the brain endothelium. Furthermore, the cytokine-in-
duced release of sEVs carry a molecular material that is able to modulate the RNA and 
protein levels within the recipient endothelial cells that correspond with changes in the 
barrier and adhesion properties of the cells. These data suggest that BEC-derived sEVs 
may contribute to the progression of endothelial injury during neuroinflammation in the 
CNS (Figure 7).  
 
Figure 7. The proposed model for the cytokine-sEV role in modulating cerebrovascular functions. (1) The incubation of 
hCMEC/D3 cells with 10 ng/mL of TNFα and IFNy increased the secretion of small EVs (cytokine-sEVs). (2) These cyto-
kine-sEVs carried elevated levels of the proinflammatory miRNA-155, as well as mRNAs of VCAM1 and ICAM1. (3) Naïve 
hCMEC/D3 cells take up cytokine-sEVs, leading to increased intracellular levels of miRNA-155 and ICAM1 and VCAM1 
in recipient hCMEC/D3 cells (4). Consequently, the endothelial resistance is decreased (5), while the firm adhesion of 
Jurkat T cells (6) is increased in recipient endothelial cells. 
In accordance with most studies analysing the EV number after an inflammatory 
challenge [38], our results suggested that BECs shed more EVs after stimulation with 
TNFα and IFNy. Additionally, we found that the number of cytokine-sEVs was signifi-
cantly higher than that of L-EVs after treatment with proinflammatory cytokines. This 
observation differs from Dozio et al., who reported that TNFα-stimulated hCMEC/D3 
cells secreted equivalent amounts of sEV and L-sEVs [20]. Hypoxic lung epithelial cells 
were found to secrete a higher quantity of L-EV-protein than sEVs [39]. However, other 
reports have described an increased number of sEVs in comparison to L-EVs isolated from 
CCM under basal conditions [40,41]. Differences in the type and number of EVs released 
following inflammatory insult are likely to be specific of the model and treatment used 
and may also depend on the protein packaging within the EVs. Our results indicate that 
sEVs may play a more relevant role than L-EVs in modulating vascular functions during 
inflammation. However, the systematic comparison of L-EV and sEV functions in the 
brain endothelium is necessary to draw more robust conclusions about potential different 
roles of these two subsets of EVs in cerebrovascular functions. 
We observed that the cytokine treatment had no effect on the size distribution (mean 
and mode) of sEVs and L-EVs, as has been previously reported [20]. However, while we 
found no changes in the mean and mode of sEVs compared to L-EVs, other studies have 
shown an increase in the mode and/or mean of L-EVs compared to sEVs, albeit with a 
great amount of overlap in the size distribution of the EVs [20,40,41]. This discrepancy is 
likely to occur due to differences in the EV isolation techniques, which have a different 
ability to recover pure EV populations [12]. Nevertheless, we found that the cytokine-L-
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EV size distribution was larger than the rest of the studied EVs evidenced by an increase 
in D90. Therefore, we are confident that our method of isolation was enriched for the dif-
ferent subsets, although a high heterogeneity was observed.  
The isolation of sEVs by differential ultracentrifugation has been reported to co-iso-
late soluble proteins [12]. For this reason, we measured the quantity of proinflammatory 
cytokines (TNFα and IFNy) remaining on the isolated sEVs. We found that the concentra-
tion of TNFα and IFNy in the sEV fraction was less than 1% of the original concentration 
to which the BECs were exposed. Moreover, this concentration was 100 times smaller than 
the lowest dose of TNFα and IFNy that induced an inflammatory response in the 
hCMEC/D3 cells [27]. Nevertheless, we cannot completely exclude that some of the re-
sponses of recipient BECs to cytokine-sEV may have been due to free TNFα and IFN, or 
to the possibility that some cytokines may also be carried within the sEVs [42,43].  
Our results are in accordance with the general view that sEVs derived from proin-
flammatory cytokine-activated cells are capable of inducing cytokine-like effects in recip-
ient cells [44]. However, most studies have investigated the role of EV communication and 
their impact on vascular functions using plasma- or serum-derived EVs with a multicel-
lular origin [45]. To our knowledge, this is the first study to evaluate the role of EVs shed 
from the brain endothelium in modulating vascular functions during inflammation. 
In the present study, we observed that cytokine-sEVs decreased the endothelial re-
sistance, whereas quiescent sEVs have no effect on the TEER. These results are in accord-
ance with previous reports that found that non-brain endothelial and other cellular origin 
EVs affect the endothelial resistance [18,46]. A decreased TEER is related to BBB permea-
bility and has been associated with the migration of bloodborne molecules into the brain 
parenchyma [22]. Therefore, it is likely BEC-derived sEVs are involved in the extravasa-
tion of these molecules during inflammation at the BBB. We also showed a small transient 
effect of sEVs on the permeability of small tracers. Future experiments will help elucidate 
what other aspects of BBB permeability are affected by sEVs in inflammation. 
We also observed that T-cell adhesion to BECs was twice as high in the presence of 
proinflammatory cytokines compared to cytokine-sEVs by themselves. Previous reports 
have reported a similar difference, although these differences vary according to the cell 
type and inflammatory stimulus [47,48]. We speculate that sEVs might finetune the re-
sponse of naïve endothelial cells to neuroinflammation. A recent study showed that naïve 
HUVECS and human monocytic cells (THP-1) treated with EVs derived from human pri-
mary umbilical vein endothelial cells (HUVECs) stimulated with TNFα induced proin-
flammatory markers and increased monocyte adhesion and transmigration in vitro [48]. 
The data suggest that the secretion of inflammation-induced endothelial sEVs modulates 
the capability of naïve endothelial cells in binding leukocytes. 
The modulation of cellular functions by sEVs is mediated by different mechanisms, 
including the release of EV cargo and/or protein–protein interaction [49]. Specifically, 
miRNA-155-5p has been previously shown to be transferred from sEVs to modulate the 
functions of the acceptor cells [50]. MiRNA-155-5p is a master regulator of cellular inflam-
mation [51,52]. Previous research in our group demonstrated that endogenous miRNA-
155-5p expression affected the cell activation and function of brain endothelial cells in in-
flammation [25,28]. Here, we observed an increased expression of miRNA-155-5p in both 
cytokine-sEVs and naïve BECs treated with cytokine-sEVs, while other inflammation-as-
sociated miRNAs were not changed. This was consistent with the current understanding 
that there is a variability between the expression of vesicular RNAs and the secreting 
cells/tissue [53]. However, whether miRNA-155-5p-enriched sEVs modulate TEER and/or 
leukocyte adhesion to BECs is still unknown.  
Only ICAM1 and VCAM1 protein levels were upregulated in recipient BECs after 
incubation with cytokine-sEVs, whereas no changes were found in occludin and claudin-
5. This suggests that a cytokine-sEV-induced reduction in endothelial resistance is not due 
to a downregulation of TJ proteins but may be due to alterations of the subcellular location 
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of proteins such as ZO-1 or VE-cadherin. This is supported by a study using plasma-de-
rived EVs from MS patients, which showed that the decreased endothelial resistance was 
caused by reorganisation of the junctional complexes [18]. We also confirmed that block-
ing VCAM1 with neutralising antibodies [54] decreased the T-cell adhesion to BECs (Fig-
ure 6e). This result was not unexpected, since this protein has been described to play a 
crucial role in modulating leukocyte adhesion to the endothelium [33]. As the blocking of 
ICAM1 did not affect the endothelial functions, we speculate that the ICAM1 contribution 
to sEV-induced T-cell adhesion is minor in comparison to VCAM1, given that the ICAM1 
protein levels in the recipient cells were lower than VCAM1 after cytokine-sEV treatment.  
Interestingly, Cerutti et al. showed that the overexpression of miRNA-155-5p in brain 
endothelial cells indirectly increased the levels of ICAM1 and VCAM1 [28]. Therefore, we 
speculate that the miRNA-155/ICAM1/VCAM1 axis is likely to be involved in inducing the 
effect of cytokine-sEVs in the brain endothelium. However, we cannot rule out the possi-
bility of alternative pathways mediating an increase in VCAM1 and ICAM1. 
5. Conclusions 
The findings from the current study indicated a novel role for brain endothelial-de-
rived sEVs in promoting and perpetuating endothelial dysfunction during inflammation. 
Our data suggest that this mechanism may be driven in part by the transmission and/or 
induction of the proinflammatory modulator miRNA-155-5p, as well as adhesion mole-
cules ICAM1 and VCAM1. The results from this manuscript propose a novel mechanism 
of communication among brain endothelial cells during neuroinflammation 
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